Topical delivery of heparin from PLGA nanoparticles entrapped in nanofibers of sericin/gelatin scaffolds for wound healing
[Display omitted] Skin regeneration is one of the most important issues in tissue engineering. Research on more effective biomaterials that will enhance regeneration while enabling requirements of a healing skin site is an important challenge in skin tissue engineering. In this study, heparin was en...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2021-03, Vol.597, p.120207-120207, Article 120207 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
Skin regeneration is one of the most important issues in tissue engineering. Research on more effective biomaterials that will enhance regeneration while enabling requirements of a healing skin site is an important challenge in skin tissue engineering. In this study, heparin was encapsulated in Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) which were then incorporated into Sericin/Gelatin (Ser/Gel) nanofibers during the electrospinning process in order to develop a combined system that has controlled release approach, besides the ability to help the regeneration of skin tissue by the involvement of biopolymers; gelatin, and sericin. The loading capacity and heparin encapsulation efficiency in the nanoparticles were determined as 30.04 mg/g of polymer and 60%, respectively. Cumulative release of heparin from NPs for 1 week was faster than from NPs loaded gelatin scaffolds and from dual protein (Ser/Gel) scaffolds with ratios: 1/7 and 1/2 (approximately 85%, 65%, 55%, and 40%, respectively). Sericin addition slowed down the degradation properties of the scaffold. The scaffold having a Ser/Gel ratio (1/2) was found as the most promising candidate because of its proper fiber morphology, high water retention, and low degradation degree. |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2021.120207 |